Insmed discontinues development of skin condition drug
07/04/2026 21:06
April 7 (Reuters) - Insmed INSM.O said on Friday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Shreya Biswas) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Insmed
See all newsAstera Labs, CoreWeave and others rise after Nasdaq-100 inclusion
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Brief: Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings